Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.

ALL treatment: Current settings, future goals

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Short-term antidepressant treatment passes muster in bipolar depression

In the treatment of selected patients with bipolar disorder and concomitant depression, adding a short course of antidepressant to a mood stabilizer and/or an antipsychotic is effective and safe, with a low risk of switch, mixed depression, and cycle acceleration, as shown in a study.

Short-term antidepressant treatment passes muster in bipolar depression

Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem

Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.

Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem

CC-486 maintenance preserves survival benefit, QoL in older AML patients

In older patients with acute myeloid leukaemia (AML), CC-486 maintenance therapy after intensive chemotherapy (CT) with or without consolidation CT led to improved survival regardless of MRD* status, and preserved baseline QoL status, according to the QUAZAR AML-001 trial presented at ASH 2020.

CC-486 maintenance preserves survival benefit, QoL in older AML patients

Antenatal dexamethasone reduces risk of neonatal death, stillbirth

Antenatal use of dexamethasone significantly reduces the risk of neonatal death and stillbirth among women at risk of early preterm birth in low-resource countries, according to the WHO ACTION-I* study.

Antenatal dexamethasone reduces risk of neonatal death, stillbirth

Statins may protect the heart from chemo for breast cancer

07 Jan 2021 bởi

Women who received statins were less likely than those who did not to have ED* visits or hospitalizations for heart failure (HHF) following chemotherapy with anthracyclines for early breast cancer (EBC) — suggesting that statins may protect the heart against damage induced by chemotherapy, at least among older women.

Statins may protect the heart from chemo for breast cancer

Which tool is best for screening interactions between herbal supplements, anticancer agents?

The best available tool for detecting herb–drug interaction is Lexicomp, and the best free alternative is Medscape, suggests a study. However, the sensitivity and performance for detecting herb–drug interaction is far lower than for drug–drug interactions and quite poor overall.

Which tool is best for screening interactions between herbal supplements, anticancer agents?

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer

07 Jan 2021 bởi

The novel third-generation ALK* inhibitor lorlatinib outdid the first-generation inhibitor crizotinib as treatment for previously untreated advanced ALK+ non-small-cell lung cancer (NSCLC), according to the interim results of the CROWN trial.

First-line lorlatinib trumps crizotinib for advanced ALK+ lung cancer